ALIPAY
16.5.2023 07:25:36 CEST | Business Wire | Press release
Ahead of 2023 International Museum Day, Digital to Asia, an Italian digital marketing agency focused on Chinese market, and Way Experience, an Italian production company that creates unique AR and VR immersive experiences for the culture and tourism sectors, today announced the launch of an innovative virtual tour featuring Leonardo da Vinci’s art on Alipay, the leading digital open platform in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005914/en/
A virtual museum launched by Italian companies on Alipay platform, exhibiting Leonardo da Vinci’s works displayed across different museums around the world (Photo: Business Wire)
The tour, with a 360-degree view powered by immersive 3D technologies, allows Chinese art lovers to see and learn about Leonardo da Vinci’s works that are displayed across different museums around the world into a single virtual museum. Italian designers and creatives took inspiration from European Renaissance architecture for the look and feel of the virtual museum. The virtual museum also includes a Chinese language guide of Leonardo da Vinci’s life and his most iconic paintings such as the Mona Lisa and The Last Supper, as well as his inventions, such as the flying machine, collected from Codex Atlanticus.
Chinese art lovers can purchase the tour through a mini program, named Yunshang Mibao, on the Alipay platform.
The virtual museum on Alipay is the latest example of how technology is being used to bring history and culture to life for a new generation of consumers. By partnering with Alipay, Digital to Asia and Way Experience are able to offer Chinese art lovers a unique and immersive experience that would not be possible otherwise.
“Emerging technologies give us the opportunity to create virtual places and travel inside them to discover humanity's greatest masterpieces. We are excited to partner with the Alipay platform to bring innovative sight-seeing experiences to Chinese consumers,” said Marco Pizzoni, co-founder and CEO of Way Experience, “Together with Digital to Asia, we created a virtual tour of Leonardo da Vinci’s masterpieces for Chinese art lovers in a Renaissance-like museum with inspiration drawn from different places that represent Italian history.”
“As an agency specializing in digital marketing strategies for Asian markets, we always stay ahead of the curve. Given mobile-savvy Chinese consumers’ open attitude towards new and innovative experiences, we have been working with Italian partner Way Experience and leading platform Alipay for the past several months to provide users with a Leonard da Vinci themed virtual tour that they have never experienced before,” said Giuliana Zagarella, General Manager of Digital to Asia. “Alipay’s deep connection with users and the availability of various digital tools on the platform make it the perfect platform partner for us in China.”
“Digital technology is making it possible for people to transcend the limitations of time and space and experience different cultures and art from all over the world. As a platform, Alipay is committed to supporting businesses to better engage with digital savvy audiences,” said Nicole Wang, Alipay’s digital solution expert for the museum industry.
The culture and tourism industries are becoming increasingly digital, with companies using more digital solutions to create new experiences for customers. According to a survey by Accenture, senior travel industry executives believe that technology is becoming more important in developing long-term business success1.
By the end of 2022, more than 2,000 museums have been using the Alipay platform to improve their digital operations and connect with museum enthusiasts, particularly younger, mobile-savvy generations. These museums leverage digital tools and services offered on Alipay, such as mini-programs, lifestyle accounts, live streaming, and blockchain-based digital collectibles to improve engagement with visitors.
According to OECD’s Tourism Trends and Policies report in 20222, “Digital technologies present wide-reaching opportunities to facilitate increased reach to consumers, productivity, and the transition to a more sustainable and inclusive future, delivering benefits to micro and small businesses and local communities as well as to visitors”.
About Way Experience
Founded in 2019, Way Experience is an Italian production company that creates unique AR and VR immersive experiences for the culture and tourism sectors. Way Experience comes up with, produces and shares innovative projects designed for the general public through both phygital experiences and full digital products. We are a team of digital creatives, storytellers and virtual artists whose mission is sharing culture, knowledge and beauty through disruptive experiences that enrich everyone who lives them.
About Digital to Asia (Branding Records Group)
Digital to Asia is a digital marketing agency founded in 2017 that supports European Brands in promoting products and services towards Chinese customers. Digital to Asia designs digital marketing strategies for Asian markets with significant and measurable results, starting from market analysis, defining sales and communications strategies and searching for suitable Chinese partners to develop online sales and brand promotions. Moreover, Digital to Asia is expert on travel marketing, with the aim to guide Chinese customers discover European attractions while ensuring the most amazing lifestyle and luxury shopping experiences.
About Alipay
In the digital era, Alipay has evolved from a trusted payment tool to an open platform that connects businesses, institutions, service providers, and other partners with consumers. Alipay enables partners from various industries to offer safe and convenient payment options. It also enables partners to communicate and deliver different digital services to their customers in China through Alipay mini programs, lifestyle accounts and other tools. The Alipay platform has connected over 80 million businesses with more than one billion consumers.
____________________________
1 https://www.accenture.com/content/dam/accenture/final/industry/travel/document/Travel-Technology-Vision-2022.pdf
2 https://www.oecd.org/cfe/tourism/oecd-tourism-trends-and-policies-20767773.htm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005914/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom